They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Gardasil, which prevents cancers caused by the human papillomavirus (HPV), has been ... compared with analyst forecasts of around $7.4 billion. Total revenue rose to $15.6 billion from $14.6 ...

Why it matters: HPV vaccine Gardasil has been hit by economic weakness ... We anticipate peak sales for pulmonary hypertension drug Winrevair around $4 billion, and we're bullish on the mRNA ...

Gardasil vaccine protects against cancer-causing human papilloma virus or HPV infections. The pause announcement comes a month after Merck received approval in China for use of the vaccine in males.

Gardasil, which prevents cancers caused by the human papillomavirus (HPV), has been ... compared with analyst forecasts of around $7.4 billion. Total revenue rose to $15.6 billion from $14.6 ...

Gardasil is a vaccine that prevents cancer from HPV, the most common sexually transmitted ... posted nearly $1.4 billion in sales, up 9% from the same period a year ago. The company said higher ...

Gardasil, which prevents cancers caused by the human papillomavirus (HPV), has been one of Merck's ... compared with analyst forecasts of around $7.4 billion.